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Inherited aminoacidurias are caused by defective amino-acid
transport through renal (reabsorption) and in many cases
also small intestinal epithelia (absorption). Recently, many
of the genes causing this abnormal transport have been
molecularly identified. In this review, we summarize the latest
findings in the clinical and molecular aspects concerning the
principal aminoacidurias, cystinuria, lysinuric protein
intolerance, Hartnup disorder, iminoglycinuria, and
dicarboxylic aminoaciduria. Signs, symptoms, diagnosis,
treatment, causative or candidate genes, functional
characterization of the encoded transporters, and animal
models are discussed.
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Amino-acid transport is vital to life and for many aspects of
physiology and pathophysiology. The study of amino-acid
transport in epithelial cells, of intestinal or renal proximal
tubular origin, and the expression of transporter proteins in
heterologous systems, for example, Xenopus laevis oocytes,
have been immensely fruitful and provided many clues in the
past few years. Furthermore, genetic studies in patients with
specific aminoacidurias, and phenotypic observations in
knockout mice, have brought several major contributions
to our understanding of epithelial amino-acid transport. The
recognition of changes in individual amino-acid levels in
urine and plasma of patients has further supported research
and progress in this field.
The association of a disease with an amino-acid transport
defect was suggested already a century ago by Sir Archibald
Garrod,1,2 the ‘father’ of metabolic medicine and biochemical
genetics. He described cystinuria as cause of nephrolithiasis
in his third and fourth Croonian lectures. In the 1950s, a
disorder with pellagra-like symptoms associated with ‘cons-
tant renal aminoaciduria’ was named after the affected
members of a British family as Hartnup disorder.3 Another
new rare disorder was first described shortly thereafter in
Finnish patients, who excreted large amounts of dibasic
amino acids in the urine, had low plasma concentrations of
these amino acids, and severe symptoms including coma. The
disorder was called lysinuric protein intolerance (LPI) and
was later attributed to an epithelial amino-acid transport
defect, even though it resembled much more a classical
metabolic disorder with signs and symptoms of elevated
blood ammonia.4
Standard urinary amino-acid screening resulted in the
identification of two other asymptomatic aminoacidurias,
iminoglycinuria5–7 and dicarboxylic aminoaciduria.8,9
In principal, clinical consequences in specific aminoacid-
urias can arise from either the deficiency of particular amino
acids (lack of absorption in the intestine and urinary loss) or
the precipitation of certain amino acids (cystine) in the urine.
The study of aminoacidurias was greatly facilitated by the
advent of paper chromatography10 and then ion exchange
chromatography in the 1950s.11 The latter method can
reliably detect and quantify minute amounts of individual
amino acids in body fluids like plasma and urine, or even in
subcellular compartments. The individual amino acids are
separated based on their distinct physicochemical properties
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by high-pressure liquid chromatography in specialized
columns (packed with cation exchange resins). The principle
of the most commonly used assay is the formation of colored
compounds from the reaction of amino or imino acids with
ninhydrin. The amount of light absorbed at two wavelengths,
570 nm (amino acids) and 440 nm (imino acids), is
proportional to the quantity of amino acids present. Even
though amino acids can nowadays be detected by different
and even more sophisticated methods, ion exchange
chromatography has remained the method of choice for
clinical practice.
The pathophysiology of aminoacidurias teaches us a lot
about epithelial transport physiology. In intestinal and
proximal kidney tubule epithelia, specific amino-acid trans-
porters, located on both the luminal and basolateral
membranes, together perform an ‘uphill’ transcellular trans-
port, that is, against the concentration gradient back into the
extracellular blood compartment. This net transport is very
efficient, and in the renal proximal tubule up to 99% of free
amino acids, filtered through the glomerulus, are reabsorbed
and thus retained by the organism.
Initially, amino-acid transport types were classified
according to specificity and sodium dependence described
as systems, a classification that is still used by physiologists.
Examples of such systems are, for instance, B0 (broad
selectivity sodium-dependent neutral amino-acid transport),
b0,þ (broad selectivity sodium-independent neutral and
basic amino-acid transport), yþL (sodium-independent
basic amino-acid transport), and XAG (sodium-dependent
acidic amino-acid transport).12 With the increasing number
of molecularly identified transporters, a more homogeneous
nomenclature was necessary. The solute carrier families
(SLC) nomenclature, based on gene homology, was intro-
duced by the Human Genome Organization (HUGO).
Unfortunately, some confusion persists, as this system is
based on homology rather than on function. In addition,
protein names are not necessarily following specific rules. For
the purpose of this review, the specific aminoacidurias
identified so far (see Table 1) were classified by the chemical
properties of the amino acids abnormally excreted (that is,
neutral, basic (cationic), acidic (anionic), or imino acids).
Amino acids mentioned are L-forms unless specified
otherwise. Gene names according to HUGO are mentioned
first followed by agreed and commonly used protein names,
for example, SLC6A19 (B0AT1).
CYSTINURIA (OMIM #220100)
Clinical findings
Patients with cystinuria often present with nephro- or
urolithiasis at almost at any age with a clear preference in
childhood due to elevated urinary cystine. Kidney stones are
radio opaque, although less than calcium-containing ones,
and easily diagnosed by ultrasound examinations. Stones
often form in the bladder and the presence of a bladder stone
in a child should always prompt consideration of cystinuria.
Early diagnosis is important, as it allows prevention or
diminution of kidney stones. Diagnostically, urinary levels of
dibasic amino acids lysine, arginine, and ornithine, and most
prominently, of cystine are constantly elevated (for example,
cystine up to 50 times normal). Plasma levels of these amino
acids in general are at the lower end of the normal range.
The clinical problems arise only from the elevated urinary
cystine, which precipitates within the urinary tract and forms
cystine stones due its low solubility. Urine microscopy reveals
Table 1 | Aminoacidurias genetically elucidated in human
Aminoaciduria Gene HUGO Protein Chromosome
Hallmark (elevation of
individual AA in urine)
Cystinuria A SLC3A1 Solute carrier family 3 (cystine,
dibasic, and neutral amino-acid
transporters, activator of cystine,
dibasic, and neutral amino-acid
transport), member 1
rBAT 2p21 Cystine, lysine, arginine,
ornithine
Cystinuria B SLC7A9 Solute carrier family 7 (cationic
amino-acid transporter, y+ system),
member 9
b0,+AT 19q13.11 Cystine, lysine, arginine,
ornithine
Cystinuria AB SLC3A1/SLC7A9 Cystine, lysine, arginine,
ornithine
Lysinuric protein
intolerance
SLC7A7 Solute carrier family 7 (cationic
amino-acid transporter, y+ system),
member 7
y+LAT1 14q11.2 Lysine, arginine, ornithine
Hartnup disorder SLC6A19 Solute carrier family 6 (neutral
amino-acid transporter), member 19
B0AT1 5p15.33 Neutral amino acids
Iminoglycinuria ? ? ? Proline, hydroxyproline,
glycine
Dicarboxylic
aminoaciduria
? ? ? Aspartate, glutamate
HUGO, Human Genome Organization; NCBI, National Center for Biotechnology Information.
According to HUGO (http://www.genenames.org) and NCBI build 36.2.
? signifies unknown.
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characteristic and pathognomonic hexagonal crystals. The
cyanide–nitroprusside urinary test is also used, but it is not
considered specific.
Treatment
Treatment overall is nonspecific and consists mostly of a high
fluid intake to keep the urinary cystine below the solubility
threshold of about 1000 mmol l1 (at pHo7). As cystine
solubility increases with pH, alkalization of urine, typically
with potassium citrate, can be used. Chelation with
D-penicillamine or mercaptopropionylglycine, although
highly effective, is rarely used owing to serious side effects.
Overall, treatment is cumbersome and some patients lose
their kidney function at some time related to recurrent
nephro- and urolithiasis.
Physiology and molecular genetics
The overall incidence of cystinuria is estimated to be in the
range of 1:7000 births. The consequences of this disease
(bladder cystine stones) were first described almost two
centuries ago,13 but the proteins responsible for the disorder
were only molecularly defined in the last two decades.
Importantly, Charles Dent14 recognized that not only urinary
cystine but also lysine and arginine were constantly elevated
in cystinuria patients. Minor urinary elevations of ornithine
were appreciated later.
SLC3A1 (rBAT) was the first protein related to epithelial
amino-acid transport to be molecularly identified.15 When
expressed in Xenopus laevis oocytes, it induced a transport
activity for dibasic amino acids and cystine, which was
attributed to the presence of an endogenous expressed
interacting protein. This interacting protein was later
identified as SLC7A9 (b0,þAT).16,17
SLC3A1 (rBAT) and SLC7A9 (b0,þAT) are members of the
heterodimeric amino-acid transporters family (HAT)18
mediating dibasic amino acid and cystine transport from
the luminal compartment into the cells. The HAT members
are composed of two different subunits bound covalently by a
disulfide bridge:19,20 a type II glycoprotein or heavy subunit
(in this case SLC3A1 (rBAT)) and a light subunit (in this case
SLC7A9 (b0,þAT)) conferring specificity and being the
functional subunit with 12 putative transmembrane domains.
Both, which are primarily expressed in kidney and intestine,
are localized to the brush border membranes of proximal
tubules or enterocytes.20,21 By overexpression of SLC3A1
(rBAT) and SLC7A9 (b0,þAT) in an epithelial cell model
(Madin–Darby canine kidney, MDCK cells), both proteins
were shown to colocalize in the apical membrane, whereas
without expression of the heavy subunit SLC3A1 (rBAT), the
light subunit SLC7A9 (b0,þAT) was retained intracellularly.22
Therefore, SLC3A1 (rBAT) is essential for proper cell surface
expression of SLC7A9 (b0,þAT).23 The heterodimeric couple
exchanges dibasic amino acids and cystine from the tubular
lumen for intracellular neutral amino acids24 (see Figure 1).
Mutations in either interacting subunit SLC3A1 (rBAT) or
SLC7A9 (b0,þAT) cause cystinuria.15,25 Cystinuria due to
mutations in SLC3A1 (chromosomal locus 2p21) is an
autosomal-recessive trait with the heterozygous parents being
unaffected, whereas mutations in SLC7A9 (chromosomal
locus 19q13.11), leads to a mild to moderately abnormal
urinary amino-acid pattern in most obligate heterozygotes
(for example, parents), thus, can be seen as an autosomal-
dominant trait. The initial nomenclature, based on the
excretion status of obligate heterozygotes (cystinuria types I,
II (non-I), III (non-I)), has been ‘replaced’ by a more
meaningful one linked to the genotype.26 Mutations in
SLC3A1 cause cystinuria type A, mutations in SLC7A9 cause
cystinuria type B, and mutations in both genes (compound
heterozygotes) cause cystinuria type AB. The disease severity
apparently is the same in cystinuria types A and B.
A mouse model, developed by targeted disruption of the
Slc7a9 gene, exhibited a lithiasic phenotype resembling the
classic type B cystinuria. Animals develop massive hyper-
excretion of cystine and dibasic amino acids, and cystine
crystalluria, with 40% of the animals having cystine calculi in
the urinary system.27 As in humans, oral treatment of this
mouse model with D-penicillamine reduced the size and
number of calculi.28
LYSINURIC PROTEIN INTOLERANCE (OMIM #222700)
Clinical findings
Patients affected by this disorder, in general, come to medical
attention from early on in life with several significant
problems including failure to thrive and intellectual impair-
ment. Episodes of diarrhea and hyperammonemia, coinci-
ding with increased protein intake (hence the name), can
point toward the correct diagnosis. Apparently, hyperammo-
nemia is caused by an interruption of the urea cycle owing to
lack of the intermediates required by the cycle (for example,
ornithine). These patients, unfortunately, also develop
interstitial pneumonia in form of an alveolar proteinosis,
hepatomegaly and liver cirrhosis, osteoporosis, and bone
marrow involvement. Renal insufficiency can develop due to
glomerulonephritis of suspected immunological etiology.
Why this specific aminoaciduria presents as a multisystemic
disorder with hallmarks of an urea cycle defect and
immunological involvement is still a matter of debate.29
Elevations of urinary dibasic amino acids, lysine, arginine,
and ornithine are diagnostic and more pronounced than
in cystinuria; urinary cystine levels in contrast to cystinuria
are almost normal (elevated only up to about 2–3 times the
norm). In contrast to cystinuria, plasma levels of lysine,
arginine, and ornithine tend to be below the norm. Orotic acid
and homocitrulline are also elevated and can be of diagnostic
value for the discrimination to other urea cycle defects.
Treatment
Treatment is symptomatic and consists of protein restriction,
as in other urea cycle disorders, and in this case in
supplementation of citrulline. Citrulline is a precursor to
both arginine and ornithine, thus can partially restore the
defective functions of the urea cycle.
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Physiology and molecular genetics
The incidence of LPI is very low, but reaches in some
populations up to 1:50 000 births. It is caused by mutations
in SLC7A7, which, similar to cystinuria, is a member of the
HAT family. The mutations causing this autosomal-recessive
disorder have, in contrast to cystinuria, been identified
exclusively in the light subunit SLC7A7 (chromosomal locus
14q11.2)30,31 mediating transport of dibasic amino acids
from intracellular to the basolateral compartment.
Xenopus laevis oocytes expression of its heavy subunit,
SLC3A2 (4F2hc), induced transport of neutral and cationic
amino acids, but not of cystine, resembling the amino-acid
exchange system called yþL.32–34 It was later shown that this
transport was not mediated by this exogenous heavy chain,
but due to an endogenously expressed Xenopus light subunit
identified as SLC7A7 (yþLAT1).35–37
SLC3A2 (4F2hc) is ubiquitously expressed, whereas
SLC7A7 (yþLAT1) is highly expressed in intestine, kidney,
lungs, and leukocytes.21,36,37 Similarly to the cystinuria
transporter, SLC7A7/SLC3A2 (yþLAT1/4F2hc) localizes to
proximal tubules (S14S2bS3) and enterocytes (jejunal and
ileal), but in contrast to cystinuria to the basolateral
membranes.21,38 SLC3A2 (4F2hc), the heavy subunit of the
basolateral basic amino-acid transporter, functions as a
chaperone, assisting in the sorting of the light subunit
SLC7A7 (yþLAT1) to the plasma membrane.36,39 When
overexpressed in an epithelial cell model (MDCK cells), in the
absence of SLC3A2 (4F2hc), only a small fraction of SLC7A7
(yþLAT1) appeared at the basolateral surface (putatively
associated with endogenous SLC3A2 (4F2hc)). Whereas
overexpression of both the heavy and light subunits resulted
in their colocalization in the basolateral membrane.38 This
heterodimeric transporter effluxes, with high affinity (micro-
molar range), dibasic amino acids in exchange for neutral
amino acids and Naþ 36 resulting together with the action of
b0,þAT (SLC7A9) and its subunit rBAT (SLC3A1) in the net
reabsorption of dibasic amino acids (see Figure 1).
The significance of the clinical picture in LPI can be
explained by a more severe loss of dibasic amino acids
in comparison to cystinuria leading to an inefficient urea
cycle resulting in hyperammonemia. Obviously, a defect in
the basolateral export of dibasic amino acids (as in LPI) has
more severe consequences than a defect in the luminal
membrane (as in cystinuria). This is, in particular, attributed
to the fact that a large fraction of the nutritional amino acids,
inclusively dibasic amino acids, are (re)absorbed as di- and
tripeptides, which are then hydrolyzed intracellularly before
they are transported out of the cell through the basolateral
membrane. Some of the unique immunological features of
this disease are most probably related to the expression
EAAC1/EAAT3 
SLC1A1
AA– + Na+ + H+
AA + Na+ 
AA + Na+ 
Cystine, AA+ AA
AA
Gly, Pro, OH-Pro Gly, Pro, OH-Pro
Dicarboxylic
aminoaciduria
Iminoglycinuria
Hartnup
disorder
Cystinuria Lysinuric protein
intolerance
?
?
?
K+
B0AT1 - collection 
SLC16A19 + TMEM27
b0,+AT - rBAT 
SLC7A9 + SLC3A1
y+LAT1 - 4F2hc 
SLC7A7 + SLC3A2
Tubulus lumen
Basolateral
?
?
?
AA+
AA–
Figure 1 | Simplified scheme of identified amino transport genes/proteins related to amino-acid reabsorption (epithelial transport)
in the luminal and basolateral membranes of the renal proximal tubule. So far, only cystinuria, lysinuric protein intolerance, and
Hartnup disorder have been elucidated genetically in man. A knock out of Slc1a1 (Eaac1/Eaat3) causes dicarboxylic aminoaciduria in the
mouse. Note that amino-acid transport proteins can have subunits, which are critical for function (heteromeric amino-acid transporters/
glycoprotein-associated amino-acid transporters); Tmem27’s role for Slc6a19 was demonstrated in mice. AA, neutral amino acids; AAþ ,
basic (cationic) amino acids; AA, acidic (anionic) amino acids; Gly, glycine; Pro, proline; OH-Pro, hydroxyproline; solid lines indicate directed
transport, dashed lines indicate possible recycling processes. Modified from ref. Verrey et al.68
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profile of SLC7A7 (yþLAT1), which is much broader than
that of SLC3A1/SLC7A9 (rBAT/b0,þAT).29
A mouse model, generated by inactivation of Slc7a7,
displayed intrauterine growth retardation with only two
animals surviving the neonatal period. These two surviving
knockout mice were maintained on a low-protein diet
and citrulline supplementation, and when introduced to a
high-protein diet displayed a metabolic dysfunction almost
identical to that observed in the human syndrome.40
HARTNUP DISORDER (OMIM #234500)
Clinical findings
First recognized in the 1950s in London as a defect of neutral
amino-acid transport, Hartnup disorder became an example
of how diet can unveil signs and symptoms of a multifaceted
disease. The protein-restricted diet imposed to the popula-
tion (World War II, postwar) revealed the defective
(re)absorption of amino acids characteristic of the Hartnup
disorder. Patients can present with signs and symptoms of
pellagra (including light-sensitive dermatitis), intermittent
cerebellar ataxia, and psychosis-like symptoms. These
symptoms, generally considered the result of niacin defi-
ciency, are thought to be caused by deficiency of tryptophan,
as this is a precursor of niacin and serotonin.
Diagnostically, elevated urinary neutral amino acids are
the first indication of the disorder. The intestinal malabsorp-
tion of tryptophan can be additionally tested by an
indican–indole test, although this is rarely used and not
readily available. The neutral aminoaciduria has to be
differentiated from generalized aminoaciduria, which would
be an obligate diagnostic hallmark of a renal Fanconi
syndrome. The most common cause of the renal Fanconi
syndrome in childhood is cystinosis, a treatable lysosomal
storage disorder.
Treatment
Currently, patients from ‘protein supersaturated’ countries
are often recognized only by newborn screening programs, as
they are asymptomatic. The question remains whether these
patients should or need to be treated at all. Patients with
pellagra-like symptoms are treated with niacin oral replace-
ment, which reverses the clinical features of the disorder.
Physiology and molecular genetics
The incidence of Hartnup disorder is estimated to be in the
range of 1:15 000 births. Mutations in SLC6A19, encoding the
neutral amino-acid transporter B0AT1, mediating neutral
amino-acid transport from the luminal compartment into
the cells (see Figure 1), are causative for autosomal-recessive
Hartnup disorder.41,42 The molecular identification of the
transporter involved came almost 50 years after the first
description of the disorder by Baron and co-workers. In 1977,
Hartnup disorder was hypothesized to be caused by the
defect of a broad-range neutral amino-acid transport
system.43 This transport system was first characterized
in brush border membrane vesicles of kidney43,44 and
jejunum,44 where it was shown to co-transport Naþ and
various neutral amino acids.45,46 It was not until 2004 that
this transport system was molecularly identified in mice, and
then in humans, as SLC6A19 (B0AT1).41,42,47
SLC6A19 (B0AT1) co-transports Naþ and a broad range
of neutral amino acids with low affinity (millimolar
range).48,49 Unlike other members of the SLC6 family,
SLC6A19 (B0AT1) does not transport biogenic amines or
osmolites, and transport is not Cl-dependent.47,48 SLC6A19
(B0AT1) mRNA was found to be highly expressed in kidney
proximal tubule and small intestine. A localization study in
mice showed that Slc6a19 (B0AT1) is expressed in the brush
border membrane of the early portion of the proximal kidney
tubules (S1). In jejunum, the luminal expression of the
transporter follows a gradient along villi, being low in the
crypts and stronger toward the tips.50
Cloning of the human SLC6A19 gene (chromosomal locus
5p15.33) led to the identification of a deleterious splice site
mutation in members of the original British Hartnup
family.41 In the original two reports describing the cloning
of this gene, nine further deletions, missense, nonsense,
and splice site mutations causing this autosomal-recessive
disorder were identified in families from Japan and
Australia.41,42
Yet, no mouse model that mimics Hartnup disorder by
disruption of the Slc6a19 gene exists. However, a recently
characterized Tmem27 (collectrin) knockout mouse was
shown to lack Slc6A19 (B0AT1) in the kidney and to present
a massive neutral aminoaciduria without glucosuria or
phosphaturia pointing to collectrin being an obligatory
subunit of Slc6A19 in the kidney.51–53 Collectrin is predicted
to be a type I transmembrane protein. Its interactions with
SLC6A19 (B0AT1) are thought to be through non-covalent
interactions. Interestingly, this gene, TMEM27, is located on
the X chromosome. No patients with neutral amino aciduria
(similar to Hartnup disorder) and X-linked recessive
inheritance have been observed so far.
IMINOGLYCINURIA (OMIM %242600)
Clinical findings
Patients with iminoglycinuria present with elevated urinary
levels of glycine, proline, and hydroxyproline. Interestingly,
obligate heterozygotes (parents of patients) show glycinuria
only.
The patients diagnosed by newborn screening programs
should be subsequently confirmed, as iminoglycinuria can be
a normal finding in neonates, presumably reflecting tubular
immaturity. Several reports have linked iminoglycinuria to
other diseases, a finding that may have been biased due
to ascertainment errors resulting from the specific popula-
tions screened (for example, mental health institutions).
As in other aminoacidurias, it is customary to analyze
the fractional excretion of all respective amino acids to
exclude urinary losses due to elevated plasma levels. Such a
situation can occur in another metabolic disorder, hyper-
prolinemia, where urine findings can mimic iminoglycinuria
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by significantly elevated plasma proline levels exceeding
urinary reabsorption capacity.
Treatment
At present time, iminoglycinuria is considered an incidental
finding and no treatment is necessary. Whether constant
urinary glycine, proline, and hydroxyproline losses have an
impact on health is not known.
Physiology and molecular genetics
The incidence of iminoglycinuria is 1:10 000 births. The
molecular cause of autosomal-recessive iminoglycinuria is
not known at present.
Studies with amino-acid transporters expressed in hetero-
logous systems pointed to the possibility that mutations in
SLC36A1 or SLC6A20 could be causative for iminoglycinuria.
SLC36A1 encodes a proton-dependent amino-acid transpor-
ter called PAT-1, and SLC6A20 the sodium-dependent imino
transporter SIT-1.
SLC36A1 (PAT-1), as presumed imino acid carrier,
co-transports protons and proline, hydroxyproline, glycine,
L-, D-, and b-alanine, and D-serine, with low affinity
(millimolar range).54 It is expressed significantly at mRNA
level in small intestine, colon, brain, and kidney.55 SLC6A20
(SIT-1), as presumed IMINO transporter, co-transports
Naþ , proline, methylaminoisobutyrate (MeAIB), methylpro-
line, and hydroxyproline with high affinity (micromolar
range), but not glycine.56,57 The mRNA is highly expressed in
small intestine, kidney, lungs, spleen, testis, and brain.
SLC6A20 (SIT-1) localizes to the brush border membranes
of proximal tubules (S1¼ S2¼ S3) and enterocytes.50
It has been hypothesized that mutations in multiple genes,
namely SLC36A1 (PAT-1), SLC6A20 (SIT-1), and SLC6A19
(B0AT1), could be the cause of iminoglycinuria.58 However,
preliminary genetic studies by us seem to exclude SLC36A1
(PAT-1) (chromosomal locus 5q33.1) and SLC6A20 (SIT-1)
(chromosomal locus 3p21.31) as being causative for
investigated cases of iminoglycinuria.59
DICARBOXYLIC AMINOACIDURIA (OMIM 222730)
Clinical findings
A few patients with no typical clinical presentation have been
reported with an excess urinary excretion of acidic amino
acids, that is, aspartate and glutamate.8,9
Physiology and molecular genetics
An incidence of 1:35 000 births was estimated from a 25-year
screening program in Quebec (Canada).60 At first, an
inborn error in SLC1A1 (EAAC1/EAAT3), an acidic (that
is, glutamate and aspartate) amino-acid transporter (see
Figure 1), was suggested to cause this disease.61,62 The
transporter is highly expressed in the later portion of
the proximal tubule in kidney (S2, S3bS1), the brush border
of ileal enterocytes, and neurons of various brain areas.63–65
SLC1A1 (EAAC1/EAAT3) co-transports glutamate, or L- or
D-aspartate with Naþ and Hþ in exchange for Kþ from the
tubule lumen into the cell with high affinity.66 A Slc1a1
(Eaac1/Eaat3) knockout mouse developed dicarboxylic
aminoaciduria, confirming the role of EAAC1 in the
reabsorption of glutamate from the renal proximal tubules.67
Despite all this evidence, so far no mutations in the
human SLC1A1 gene (chromosomal locus 9p24) have been
identified in patients with dicarboxylic aminoaciduria.
Summary
Aminoacidurias are caused by defective amino-acid transport
systems in renal and intestinal epithelia. In the last few
decades, huge progress has been made in identifying genes
and proteins involved in the pathology of some of these
disorders. Currently, the genes involved in cystinuria, LPI,
and Hartnup disorder have been identified (see Table 1,
Figure 1). The study of the mutated proteins expressed in
heterologous systems and of genes inactivated in mice models
are tools that can be used for searching for therapies. The
large screening programs of newborns can reveal different
forms of aminoacidurias, symptomatic or not, and with that
the identification of new transporters. Some fundamental
physiological questions are not solved; for example, it is not
clear why with SLC7A7 (b0,þAT) and SLC7A9 (yþLAT1)
transcellular (re)absorption of dibasic amino acids is
mediated by obligatory exchangers that expressed alone
would produce a net secretion of neutral amino acids? What
is the identity of the basolateral transporter(s) for neutral
amino acids? What are the identities of the luminal and
basolateral transporters for acidic amino acids? Which other
proteins are responsible for the (re)absorption of imino acids
and glycine? What is the basis for the immunological findings
of alveolitis and glomerulonephritis in LPI? Pursuing the
answers to these questions is important to help understand
the complex physiology of amino-acid regulation in the body
and their role in human pathophysiology. The elucidation of
amino-acid transport across polarized and non-polarized cell
membranes creates the possibility of modifying the natural
course of diseases by interfering with these processes.
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